Activated KrasG12D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin

[1]  L. Heasley,et al.  Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. , 2008, Molecular biology of the cell.

[2]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[3]  J. Neoptolemos,et al.  Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses , 2008, British Journal of Cancer.

[4]  S. Batra,et al.  Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia , 2008, British Journal of Cancer.

[5]  R. Labianca,et al.  Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer , 2008, BMC Cancer.

[6]  Jane L Meza,et al.  MUC4 Mucin Potentiates Pancreatic Tumor Cell Proliferation, Survival, and Invasive Properties and Interferes with Its Interaction to Extracellular Matrix Proteins , 2007, Molecular Cancer Research.

[7]  Vadim Iourgenko,et al.  RNA interference technologies and their use in cancer research , 2007, Current opinion in oncology.

[8]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Devi,et al.  siRNA-based approaches in cancer therapy , 2006, Cancer Gene Therapy.

[10]  R. Offringa,et al.  Dual effect of KrasD12 knockdown on tumorigenesis: increased immune-mediated tumor clearance and abrogation of tumor malignancy , 2005, Oncogene.

[11]  A. Adjei,et al.  K-ras as a target for cancer therapy. , 2005, Biochimica et biophysica acta.

[12]  H. Beug,et al.  Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.

[13]  B. Meibohm,et al.  SYBR Green-based real-time PCR allelic discrimination assay for beta2-adrenergic receptor polymorphisms. , 2005, Analytical biochemistry.

[14]  A. Cano,et al.  Upregulation of MMP-9 in MDCK epithelial cell line in response to expression of the Snail transcription factor , 2005, Journal of Cell Science.

[15]  J. Fleming,et al.  Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras–Directed Therapy , 2005, Molecular Cancer Research.

[16]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[17]  G. Berx,et al.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells , 2005, Oncogene.

[18]  F. Motoi,et al.  Pancreatic Cancer Registry in Japan: 20 Years of Experience , 2004, Pancreas.

[19]  R. DePinho,et al.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. , 2004, Cancer cell.

[20]  J. Downward.  PI 3-kinase, Akt and cell survival. , 2004, Seminars in cell & developmental biology.

[21]  S. Batra,et al.  MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFβ2 , 2004, British Journal of Cancer.

[22]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[23]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[24]  A. Tolcher,et al.  Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. , 2003, Seminars in oncology.

[25]  S. Meroueh,et al.  Cell surface association of matrix metalloproteinase-9 (gelatinase B) , 2003, Cancer and Metastasis Reviews.

[26]  D. Stacey.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. , 2003, Current opinion in cell biology.

[27]  W. Dalton,et al.  The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells , 2003, Leukemia.

[28]  R. Bernards,et al.  Stable suppression of tumorigenicity by virus-mediated RNA interference. , 2002, Cancer cell.

[29]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[30]  S. Lian,et al.  Unique K-ras mutational pattern in pancreatic adenocarcinoma from Taiwanese patients. , 2002, Cancer letters.

[31]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[32]  Ying Zhang,et al.  Overexpression of copper zinc superoxide dismutase suppresses human glioma cell growth. , 2002, Cancer research.

[33]  A. Adjei,et al.  Blocking oncogenic Ras signaling for cancer therapy. , 2001, Journal of the National Cancer Institute.

[34]  G. Clark,et al.  The importance of being K-Ras. , 2000, Cellular signalling.

[35]  C. Damsky,et al.  FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.

[36]  L. Feig.  Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases , 1999, Nature Cell Biology.

[37]  G. Christofori,et al.  The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. , 1999, Trends in biochemical sciences.

[38]  A. Ridley,et al.  Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. , 1998, Molecular biology of the cell.

[39]  T. Sugimura,et al.  Suppression of Ki‐ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki‐ras mutation but not those without Ki‐ras mutation , 1997, Molecular carcinogenesis.

[40]  C. Moskaluk,et al.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. , 1997, Cancer research.

[41]  J. Bertino,et al.  K-ras modulates the cell cycle via both positive and negative regulatory pathways , 1997, Oncogene.

[42]  F. Sarkar,et al.  Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma , 1997, International journal of pancreatology : official journal of the International Association of Pancreatology.

[43]  F. McCormick,et al.  Biochemical Characterization of a Novel KRAS Insertion Mutation from a Human Leukemia* , 1996, The Journal of Biological Chemistry.

[44]  Teruhiko Yoshida,et al.  Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. , 1995, Cancer research.

[45]  C. Caldas,et al.  K-ras mutation and pancreatic adenocarcinoma , 1995, International journal of pancreatology : official journal of the International Association of Pancreatology.

[46]  J. Devière,et al.  Detection of c-Ki-ras gene codon 12 mutations from pancreatic duct brushings in the diagnosis of pancreatic tumours. , 1995, Gut.

[47]  N. Kohl,et al.  Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Urano,et al.  Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. , 1993, Annals of surgery.

[49]  R. Weinel,et al.  Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. , 1992, Cancer research.

[50]  T. Urano,et al.  Distinguishing Pancreatic Carcinoma From Other Periampullary Carcinomas by Analysis of Mutations in the Kirsten‐ras Oncogene , 1991, Annals of surgery.

[51]  D. Shibata,et al.  Detection of c-K-ras mutations in fine needle aspirates from human pancreatic adenocarcinomas. , 1990, Cancer research.

[52]  H. Shiku,et al.  Frequent Glycine‐to‐Aspartic Acid Mutations at Codon 12 of c‐Ki‐ras Gene in Human Pancreatic Cancer in Japanese , 1990, Japanese journal of cancer research : Gann.

[53]  M. Bar‐eli,et al.  Direct sequencing analysis of exon 1 of the c-K-ras gene shows a low frequency of mutations in human pancreatic adenocarcinomas. , 1989, Oncogene.

[54]  H. Obata,et al.  Frequency and Types of Point Mutation at the 12th Codon of the c‐Ki‐ras Gene Found in Pancreatic Cancers from Japanese Patients , 1989, Japanese journal of cancer research : Gann.

[55]  C. Bartram,et al.  High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas , 1989, International journal of cancer.

[56]  Frank McCormick,et al.  ras GTPase activating protein: Signal transmitter and signal terminator , 1989, Cell.

[57]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[58]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[59]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[60]  Takashi Takahashi,et al.  K-ras gene mutation enhances motility of immortalized airway cells and lung adenocarcinoma cells via Akt activation: possible contribution to non-invasive expansion of lung adenocarcinoma. , 2004, The American journal of pathology.

[61]  M. Takeichi.  Morphogenetic roles of classic cadherins. , 1995, Current opinion in cell biology.

[62]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.